TNBC Awareness Month | GileadPro

Banner patients TNBC page

At Gilead, we are committed to improving the lives of patients with metastatic Triple-Negative Breast Cancer.
Know more
5 Facts about TBNC
  1. This form of breast cancer does not have any of the three common tumor markers (receptors for estrogen, progesterone or the growth factor HER2)1,2
  2. This is why TNBC offers fewer targets for specific tumor therapy.2
  3. Each year, 6600 people in Switzerland are diagnosed with breast cancer and about 15-20% of them are given the diagnosis TBNC.2,3
  4. TNBC particularly affects younger women under 40 years of age.2
  5. Despite incredible progress in breast tumor therapy, TNBC is more aggressive and more difficult to treat than other breast cancers.1,2
Banner TNBC page

Gilead is committed to fighting breast cancer

Gilead supports TNBC Awareness Day to highlight the stories and struggles of women with TNBC. Early diagnosis and effective treatment are crucial for this form of breast cancer. The company is committed to advancing innovative medicines to treat life-threatening diseases like cancers, among them breast cancer.

References

  1. Swissmedic (Swiss Agency for Therapeutic Products. Trodelvy® (active substance: sacitzuzumab govitecan). https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-trodelvy.html. (Download: 23.02.23)
  2. Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022 Jan 25;9:836417.
  3. https://www.krebsliga.ch/ueber-krebs/krebsarten/brustkrebs
CH-TRO-0236, 03/23